8-K: Arcadia Biosciences Q3 2025: Zola Growth, Merger Delay

Arcadia Biosciences reports mixed Q3 2025 results with Zola revenue growth and strong margins, but faces merger timing uncertainty due to a federal government shutdown.

Summary

• Total revenues for the third quarter of 2025 were $1.302 million, a 15% decrease compared to the same period in 2024.
• Year-to-date 2025 total revenues increased 3% to $3.957 million compared to the same period in 2024.
• Zola coconut water revenues increased 26% year-to-date compared to the same period in 2024.
• Gross profit margins exceeded 30% for the eleventh consecutive quarter.
• Selling, General, and Administrative (SG&A) expenses are at an all-time low.
• The cash balance declined by $257,000 to $1.1 million as of September 30, 2025.
• Net income attributable to common stockholders for Q3 2025 was $856,000 ($0.63 per share), a $2.5 million improvement from Q3 2024.
• Net loss attributable to common stockholders for the first nine months of 2025 was $1.0 million ($0.73 per share), a $2.0 million improvement from the same period in 2024.
• A credit loss of $4.7 million was recognized for the remaining outstanding principal, accrued interest, and other related receivables from the Above Food Promissory Note.
• The company holds 2.7 million shares of Above Food Ingredients Inc. stock as partial repayment of the $6 million principal amount of the note receivable.
• The pending business combination with Roosevelt Resources is delayed due to an ongoing federal government shutdown.

Sentiment

Score: 5

Explanation: The filing presents a mixed financial picture with strong operational performance in its core Zola product line and improved net income for the quarter, offset by an overall Q3 revenue decline and a significant credit loss. The delay in the strategic merger adds a layer of uncertainty.

Positives

• Zola coconut water revenues grew 26% year-to-date, entirely offsetting the absence of GLA sales from 2024.
• Gross profit margins have consistently exceeded 30% for eleven consecutive quarters, demonstrating strong operational efficiency.
• SG&A expenses reached an all-time low, reflecting effective cost management.
• The cash balance decline was minimal, decreasing by only $257,000 to $1.1 million, which exceeded expectations.
• Net income attributable to common stockholders for Q3 2025 improved by $2.5 million year-over-year to $856,000.
• Net loss attributable to common stockholders for the first nine months of 2025 improved by $2.0 million year-over-year to $1.0 million.

Negatives

• Total revenues decreased by $235,000, or 15%, during the third quarter of 2025 compared to the same period in 2024, primarily due to the absence of GLA oil sales and a large customer initial sell-in in the prior year.
• A significant credit loss of $4.7 million was recognized for the remaining outstanding principal and accrued interest on the Above Food Promissory Note.
• The first payment of principal and accrued interest under the Above Food Promissory Note, due on May 14, 2025, had not been paid as of September 30, 2025.

Risks

• Uncertainty exists regarding the timing of the pending business combination with Roosevelt Resources due to several factors, including an ongoing federal government shutdown.
• The company's ability to obtain sufficient funding required to continue operations and planned activities.
• The ability to obtain stockholder approvals required to complete the proposed business combination transaction with Roosevelt Resources and to satisfy the closing conditions.
• The occurrence of any event, change, or other circumstance or condition that could give rise to the termination of the proposed business combination transaction.

Future Outlook

The pending business combination with Roosevelt Resources is still in progress, but its timing is uncertain due to several factors, including an ongoing federal government shutdown. Arcadia intends to mail a definitive proxy statement/prospectus to stockholders after the Registration Statement on Form S-4 is declared effective by the SEC.

Management Comments

• "We are very pleased with our performance for the third quarter of 2025."
• "Zola coconut water revenues were flat year-over-year in the third quarter as we overlapped the initial sell-in to Zola’s largest customer during the third quarter of 2024. However, on a year-to-date basis, Zola coconut water revenues have grown 26% and more than offset $700,000 in GLA sales in 2024 that did not occur in 2025."
• "Additionally, our gross margins have now exceeded 30% for eleven consecutive quarters, SG&A expenses are at an all-time low and our cash management exceeded our expectations."
• "Our pending business combination with Roosevelt Resources is still in progress, but uncertainty exists regarding the timing due to several factors including the ongoing federal government shutdown that went into effect over a month ago. We continue to monitor events closely, but the shutdown is obviously a situation that is outside of our control."

Industry Context

The company's focus on innovative wellness products, particularly Zola coconut water, continues to show strong year-to-date growth, indicating a positive trend in its core consumer product segment. The strategic shift away from certain agricultural assets (GoodWheat, GLA oil) and the pursuit of the Roosevelt Resources merger suggest a broader restructuring or re-focusing of the business. The delay in the merger due to a federal government shutdown highlights external macro-environmental factors that can impact strategic corporate actions across various industries.

Comparison to Industry Standards

• The consistent gross profit margins exceeding 30% for eleven consecutive quarters suggest strong operational efficiency and pricing power within the competitive wellness beverage market, potentially outperforming some industry peers.
• The 26% year-to-date growth in Zola revenues indicates robust performance in its primary product line, which could be above average for established brands in the coconut water or functional beverage categories.
• The significant credit loss on the Above Food Promissory Note is a company-specific event related to an asset sale, making direct industry comparison difficult without specific benchmarks for similar transactions in the agricultural biotech sector.

Corporate Governance

Related Party Transactions

• The proposed all-stock business combination with Roosevelt Resources, LP, as detailed in the Securities Exchange Agreement.

Stakeholder Impact

• Shareholders: Will be required to vote on the proposed merger with Roosevelt Resources, potentially facing dilution from new share issuance. Share price may be influenced by mixed financial results, the credit loss, and merger delays.
• Employees: Potential changes or integration efforts related to the pending business combination with Roosevelt Resources.
• Customers: Continued availability and growth of Zola products, which are a key revenue driver.
• Creditors: Impacted by the recognized $4.7 million credit loss on the Above Food Promissory Note, indicating a potential default or non-payment risk.

Next Steps

• Monitor events closely regarding the federal government shutdown and its impact on the Roosevelt Resources merger timing.
• Mail a definitive proxy statement/prospectus to stockholders after the Registration Statement on Form S-4 is declared effective by the SEC.
• Hold a meeting of stockholders to consider matters relating to the proposed transaction and other matters.
• Pursue resolution of the remaining outstanding balance of the Above Food Promissory Note.

Key Dates

Recommendation

The company exhibits strong operational performance in its core Zola segment with robust year-to-date revenue growth and consistent gross profit margins, alongside effective cost control. However, the overall Q3 revenue decline and the substantial credit loss from the Above Food Promissory Note introduce significant financial concerns. The delay in the strategic merger with Roosevelt Resources adds further uncertainty regarding the company's future structure and direction. Given these mixed signals and pending major strategic events, a 'hold' recommendation is prudent until there is greater clarity on the merger's completion and the resolution of the outstanding note receivable.

Keywords

Arcadia Biosciences, RKDA, Q3 2025, financial results, Zola, coconut water, gross margins, SG&A, cash balance, Roosevelt Resources, business combination, merger, federal government shutdown, Above Food, credit loss, wellness products